Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients. Barro C, Healy BC, Saxena S, Glanz BI, et al. Mult Scler 2022 Nov 30:13524585221137697. doi: 10.1177/13524585221137697.

Read + Share

Amedeo Smart

Independent Medical Education

Barro C, Healy BC, Saxena S, Glanz BI, et al. Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients. Mult Scler 2022 Nov 30:13524585221137697. doi: 10.1177/13524585221137697.
PMID: 36448331